Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

U.K. Cancer Research Program Aims at Bespoke Treatment, FT Says

Aug. 22 (Bloomberg) -- The U.K. will start its first nationwide genetic testing program for cancer patients in September, with government, charitable and private commercial support, the Financial Times reported.

Cancer Research U.K. is leading the program, which is aimed at tailoring patients’ treatments to the genetic nature of their tumors, the newspaper said.

Initially, seven hospitals and three laboratories will collect and analyse 9,000 samples from six common cancers: breast, bowel, lung, prostate, ovary and melanoma; the samples will be tested for genes and mutations that have been identified as being likely to play a role in the development of the disease, the FT said.

That is likely to generate a coordinated program of personalised cancer treatment based on genetic testing, the newspaper said.

AstraZeneca Plc, Pfizer Inc. and PA Consulting Group will be working with Cancer Research and the National Health Service on the project, the FT said.

To contact the reporter on this story: Alan Purkiss in London on apurkiss@bloomberg.net.

To contact the editor responsible for this story: Colin Keatinge at ckeatinge@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.